Vascular Biogenics Ltd (VBLT)

[davidal66]

I thought the same thing... didn't Dror previously guide towards the year end for initiation of phase III ovarian trial. It will be interesting to see how he powers the trial--how many patients... 100-200 isn. It will also be interesting to see what the SOC arm will be... since standard of care by definition would be Avastin failures for the most part; can they do a SOC arm which is only chemo??? or, could they allow these patients to get chemo--or some other treatment at the discretion of the clinician, but there would be a risk of then losing SOC patients to clinical trial. Maybe they will do one arm of VB111 plus chemo and compare that to a clinician choice which could be anything... chemo OR clinician's choice. I'm also interested in progress in their earlier preclinical asset addressing mete static disease.